Showing posts with label hedgehog pathway. Show all posts
Showing posts with label hedgehog pathway. Show all posts
Tuesday, June 29, 2010
Review: Targeting the Hedgehog pathway in cancer - abstract
"The orally available compound, GDC-0449, is the farthest along in clinical development. Initial clinical trials in basal cell carcinoma and treatment of select patients with medulloblastoma have shown good efficacy and safety."
add your opinions
GDC-0449
,
hedgehog pathway
Tuesday, May 25, 2010
Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers
"Vismodegib is currently undergoing phase II clinical trials for the treatment of advanced BCC, metastatic colorectal cancer, ovarian cancer, MB and other solid tumors. Because of its low toxicity and specificity for the Hh (hedgehog) pathway, this drug has potential advantages compared with conventional chemotherapy, and may also be used in combination treatments. Clinical trials with other Hh inhibitors are also ongoing and their therapeutic potential will need to be compared with vismodegib."
add your opinions
hedgehog pathway
,
inhibitor
,
Vismodegib
Thursday, April 01, 2010
Curis to Present at the 17th Annual Future Leaders in the Biotech Industry Conference - Hedgehog Pathway inhibitor GDC-0449 (financial news)
"Dan Passeri, Curis' President and Chief Executive Officer, will provide an overview of the status of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor. GDC-0449 is currently being developed in three Phase II clinical trials by Curis' collaborator Genentech, including in a pivotal Phase II trial in advanced basal cell carcinoma and Phase II trials in metastatic colorectal cancer and advanced ovarian cancer. Mr. Passeri will also discuss CUDC-101, Debio 0932 and Curis' other targeted cancer programs, in addition to other corporate activities.
There will be a corresponding webcast of the presentation, which can be accessed by visiting:
http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=CRIS&item_id=2957649
The presentation will be archived shortly after the live event and available for 30 days following the conference. In addition, it will be available for 30 days on the Investor Relations section of the Curis website at www.curis.com."
add your opinions
GDC-0449
,
hedgehog pathway
Subscribe to:
Posts
(
Atom
)